Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643774 | 0.87 | TP53 (0.55) | KMT2AMEN1TP53NPC1ROCK2 | |
| SCHEMBL1644476 | 0.85 | HPGD (0.52) | KMT2AMEN1TP53LMNAALDH1A1 | |
| SCHEMBL1285010 | 0.84 | KMT2A (0.44) | KMT2AMEN1HTTNPC1LMNA | |
| SCHEMBL1644493 | 0.84 | ALOX5 (0.57) | KMT2AMEN1TP53NPC1ROCK2 | |
| SCHEMBL1643007 | 0.81 | PDE2A (0.47) | TP53PPARG | |
| SCHEMBL3037590 | 0.80 | NPC1 (0.61) | KMT2AMEN1HTTNPC1LMNA | |
| SCHEMBL23169597 | 0.79 | MLYCD (0.50) | KMT2AMEN1HTTNPC1LMNA | |
| SCHEMBL1643824 | 0.79 | ACACB (0.47) | KMT2AMEN1HTTTP53NPC1 | |
| SCHEMBL1644482 | 0.79 | ACACB (0.47) | KMT2AMEN1HTTTP53NPC1 | |
| SCHEMBL1643038 | 0.78 | ACACB (0.46) | KMT2AMEN1TP53NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | KMT2A 4280/4885MEN1 4500/4885HTT 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.